Search

Your search keyword '"Didier Hannequin"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Didier Hannequin" Remove constraint Author: "Didier Hannequin" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
84 results on '"Didier Hannequin"'

Search Results

1. Phenotype and imaging features associated with APP duplications

2. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

3. How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

4. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.

5. New insights into the genetic etiology of Alzheimer's disease and related dementias

6. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

7. Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes

8. Recurrence of an early postzygotic rescue of an inherited unbalanced translocation resulting in mosaic segmental uniparental isodisomy of chromosome 11q in siblings

9. SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration

10. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial

11. Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers

12. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

13. Plasma NfL levels and longitudinal change rates in

14. Nucleus Basalis of Meynert Stimulation for Lewy Body Dementia: A Phase I Randomized Clinical Trial

15. Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Nonamyloid Logopenic Variant

16. Correction: Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment

17. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications

18. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes

19. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab

20. Phenotypes associated with MAPT duplications

21. Solanezumab in‐depth outcomes

22. Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment

23. Primary Progressive Aphasia Associated With

24. Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis

25. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience

26. Neurobiol Aging

27. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers

28. Biallelic Loss of Function of SORL1 in an Early Onset Alzheimer’s Disease Patient

29. Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer’s Disease

30. A panel study on patients with dominant cerebellar ataxia highlights the frequency of channelopathies

31. Les biomarqueurs du liquide cérébro-spinal dans la maladie d’Alzheimer : un outil de recherche utile dans la pratique clinique courante des consultations mémoire pour les cas complexes

32. Cognitive inhibition impairments in presymptomatic

33. Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer’s Disease Before 51 Years

34. How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

35. Neurite density is reduced in the presymptomatic phase of C9orf72 disease

36. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

37. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

38. Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP

39. Familial intracranial aneurysm, the relationship of the aortic diameter

40. Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: An MRI Study of 16 French Cases

41. Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer's disease

42. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers

43. Neurite density is reduced in the presymptomatic phase of

44. Novel VCP mutations expand the mutational spectrum of frontotemporal dementia

45. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study

46. Analysis of shared heritability in common disorders of the brain

47. O4-02-01: PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM-0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS

48. New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay

49. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer’s disease

50. Convergent genetic and expression data implicate immunity in Alzheimer's disease

Catalog

Books, media, physical & digital resources